NYSE - Nasdaq Real Time Price USD
West Pharmaceutical Services, Inc. (WST)
As of 10:57 AM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,876,400.00
2,949,800.00
2,886,900.00
2,831,600.00
2,146,900.00
Cost of Revenue
1,873,300.00
1,820,600.00
1,750,700.00
1,655,800.00
1,379,100.00
Gross Profit
1,003,100.00
1,129,200.00
1,136,200.00
1,175,800.00
767,800.00
Operating Expense
412,200.00
421,800.00
375,400.00
415,600.00
348,900.00
Operating Income
590,900.00
707,400.00
760,800.00
760,200.00
418,900.00
Net Non Operating Interest Income Expense
19,200.00
19,000.00
-2,800.00
-7,200.00
-6,800.00
Other Income Expense
-21,300.00
-28,400.00
-78,100.00
-4,100.00
-10,800.00
Pretax Income
588,800.00
698,000.00
679,900.00
748,900.00
401,300.00
Tax Provision
105,200.00
122,300.00
114,700.00
107,200.00
72,500.00
Earnings from Equity Interest Net of Tax
16,000.00
17,700.00
20,700.00
20,100.00
17,400.00
Net Income Common Stockholders
499,600.00
593,400.00
585,900.00
661,800.00
346,200.00
Diluted NI Available to Com Stockholders
499,600.00
593,400.00
585,900.00
661,800.00
346,200.00
Basic EPS
6.81
7.98
7.87
8.89
4.68
Diluted EPS
6.74
7.88
7.73
8.67
4.57
Basic Average Shares
73,325.00
74,300.00
74,400.00
74,400.00
73,900.00
Diluted Average Shares
74,025.00
75,300.00
75,800.00
76,300.00
75,800.00
Total Operating Income as Reported
571,200.00
676,000.00
734,000.00
752,300.00
406,900.00
Total Expenses
2,285,500.00
2,242,400.00
2,126,100.00
2,071,400.00
1,728,000.00
Net Income from Continuing & Discontinued Operation
499,600.00
593,400.00
585,900.00
661,800.00
346,200.00
Normalized Income
515,287.43
619,305.00
608,669.40
667,113.40
356,028.00
Interest Income
24,200.00
28,000.00
5,100.00
1,000.00
1,400.00
Interest Expense
5,000.00
9,000.00
7,900.00
8,200.00
8,200.00
Net Interest Income
19,200.00
19,000.00
-2,800.00
-7,200.00
-6,800.00
EBIT
593,800.00
707,000.00
687,800.00
757,100.00
409,500.00
EBITDA
744,400.00
844,300.00
808,400.00
879,400.00
518,600.00
Reconciled Cost of Revenue
1,873,300.00
1,820,600.00
1,750,700.00
1,655,800.00
1,379,100.00
Reconciled Depreciation
150,600.00
137,300.00
120,600.00
122,300.00
109,100.00
Net Income from Continuing Operation Net Minority Interest
499,600.00
593,400.00
585,900.00
661,800.00
346,200.00
Total Unusual Items Excluding Goodwill
-19,100.00
-31,400.00
-27,400.00
-6,200.00
-12,000.00
Total Unusual Items
-19,100.00
-31,400.00
-27,400.00
-6,200.00
-12,000.00
Normalized EBITDA
763,500.00
875,700.00
835,800.00
885,600.00
530,600.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-3,412.57
-5,495.00
-4,630.60
-886.60
-2,172.00
12/31/2020 - 3/17/1980
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
COO The Cooper Companies, Inc.
100.79
+0.88%
RGEN Repligen Corporation
142.76
+0.70%
TFX Teleflex Incorporated
191.34
+0.37%
RMD ResMed Inc.
241.77
-0.75%
BDX Becton, Dickinson and Company
225.37
-0.04%
STVN Stevanato Group S.p.A.
19.79
+0.87%
ALGN Align Technology, Inc.
223.09
-2.24%
ATR AptarGroup, Inc.
170.84
+0.56%
XRAY DENTSPLY SIRONA Inc.
18.70
+0.32%
ALC Alcon Inc.
86.06
+0.57%